ERNA vs PSA · P/E 0.0, rev $582.0K vs rev $4.82B
Eterna Therapeutics Inc (ERNA) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Eterna Therapeutics Inc (ERNA) is a biotechnology company listed on NASDAQ.
PSA (PSA) common stock.
Latest reported ERNA revenue for 2024-12-31 was $582.0K. Net income was -$44.5M. Revenue was up 755.9% from 2023-12-31 to 2024-12-31. ERNA currently screens at market cap $6.9M and trailing P/E 0.0.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
ERNA currently screens at market cap $6.9M and trailing P/E 0.0. PSA currently screens at market cap $0.
Not investment advice. Open the ERNA and PSA stock pages for the full models.
Not investment advice.